Aliases & Classifications for Dry Eye Syndrome

MalaCards integrated aliases for Dry Eye Syndrome:

Name: Dry Eye Syndrome 12 15 17
Dry Eye Syndromes 54 43 71
Tear Film Insufficiency 12
Xerophthalmia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:10140
MeSH 43 D015352
NCIt 49 C34553
ICD10 32 H04.12
UMLS 71 C0013238 C0043349

Summaries for Dry Eye Syndrome

MalaCards based summary : Dry Eye Syndrome, also known as dry eye syndromes, is related to keratoconjunctivitis sicca and keratoconjunctivitis, and has symptoms including dryness of eye and dacryops. An important gene associated with Dry Eye Syndrome is LACRT (Lacritin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dimenhydrinate and Povidone have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and salivary gland, and related phenotype is vision/eye.

Wikipedia : 74 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Dry Eye Syndrome

Diseases related to Dry Eye Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 269)
# Related Disease Score Top Affiliating Genes
1 keratoconjunctivitis sicca 33.6 TNF NGF LTF LACRT AQP5
2 keratoconjunctivitis 31.6 TNF NGF IL6
3 keratitis, hereditary 31.1 TNF IL6 FGF2
4 blepharitis 30.8 TNF PIP LTF LCN1 LACRT IL6
5 eye disease 30.8 TNF NGF LACRT IL6 FGF2 EGF
6 rosacea 30.7 TNF S100A8 IL6
7 sleep disorder 30.6 TNF IL6 BDNF
8 fibromyalgia 30.6 TNF NGF IL6 BDNF
9 irritable bowel syndrome 30.6 TNF NGF IL6 BDNF
10 keratoconus 30.3 TNF PIP IL6 HGF AQP5
11 gastritis 30.3 TNF S100A8 LTF IL6
12 juvenile rheumatoid arthritis 30.2 TNF S100A9 S100A8 IL6
13 mucositis 30.2 HGF FGF7 EGF CD44
14 crohn's disease 30.2 TNF S100A9 S100A8 IL6
15 anxiety 30.1 TNF NGF IL6 BDNF
16 corneal disease 30.0 TNF NGF LACRT IL6 FGF2 EGF
17 macular degeneration, age-related, 1 30.0 TNF IL6 FGF2 EGF BDNF
18 sleep apnea 29.8 TNF IL6 BDNF
19 skin disease 29.8 TNF S100A9 IL6 FGF7 FGF2 BDNF
20 osteoporosis 29.6 TNF IL6 HGF FGF2 EGF CD44
21 cystic fibrosis 29.4 TNF S100A9 S100A8 LTF IL6
22 inflammatory bowel disease 28.9 TNF S100A9 S100A8 MUC1 LTF IL6
23 sjogren syndrome 11.7
24 premature ovarian failure 1 11.1
25 external pathological resorption 10.7 TNF IL6
26 scorpion envenomation 10.7 TNF IL6
27 idiopathic anterior uveitis 10.6 TNF IL6
28 streptococcal toxic-shock syndrome 10.6 TNF IL6
29 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 TNF IL6
30 chronic follicular conjunctivitis 10.6 PRR4 LACRT
31 esophagitis 10.6 TNF IL6 EGF
32 autoimmune gastritis 10.6 TNF IL6 EGF
33 vulvar eccrine porocarcinoma 10.6 PIP MUC1
34 trachoma 10.6 TNF IL6 EGF
35 neurotrophic keratoconjunctivitis 10.6 NGF BDNF
36 nodular hidradenoma 10.6 PIP MUC1
37 adamantinoma of long bones 10.6 FGF2 EGF
38 polyradiculopathy 10.6 TNF NGF IL6
39 burning mouth syndrome 10.5 TNF NGF IL6
40 pneumocystosis 10.5 TNF MUC1 IL6
41 autoimmune disease of exocrine system 10.5 TNF IL6 AQP5
42 chickenpox 10.5 TNF MUC1 IL6
43 mycoplasma pneumoniae pneumonia 10.5 TNF MUC1 IL6
44 neurotic disorder 10.5 TNF IL6 BDNF
45 thoracic benign neoplasm 10.5 PIP MUC1 EGF
46 chlamydia pneumonia 10.5 TNF S100A8 IL6
47 encephalomalacia 10.5 TNF IL6 BDNF
48 sweat gland disease 10.5 TNF PIP NGF
49 breast benign neoplasm 10.5 PIP MUC1 EGF
50 peptic esophagitis 10.5 TNF S100A8 IL6

Graphical network of the top 20 diseases related to Dry Eye Syndrome:



Diseases related to Dry Eye Syndrome

Symptoms & Phenotypes for Dry Eye Syndrome

UMLS symptoms related to Dry Eye Syndrome:


dryness of eye, dacryops

MGI Mouse Phenotypes related to Dry Eye Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.28 AQP5 BDNF CD44 EGF FGF2 FGF7

Drugs & Therapeutics for Dry Eye Syndrome

Drugs for Dry Eye Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dimenhydrinate Approved Phase 4 523-87-5 441281
2
Povidone Approved Phase 4 9003-39-8
3
Dipivefrin Approved Phase 4 52365-63-6 3105
4
Glycerol Approved, Investigational Phase 4 56-81-5 753
5
Zinc Approved, Investigational Phase 4 7440-66-6 32051
6
Ethanol Approved Phase 4 64-17-5 702
7
Sorbitol Approved Phase 4 50-70-4 5780
8
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
9
Ofloxacin Approved Phase 4 82419-36-1 4583
10
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
11
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
12
Travoprost Approved Phase 4 157283-68-6 5282226
13
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
14
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
15
Menthol Approved Phase 4 2216-51-5 16666
16
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
17
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
18
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
19
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
20
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
21
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
22
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
23
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
24 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
25
Azithromycin Approved Phase 4 83905-01-5 447043 55185
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
27
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
28 Propoxycaine Approved Phase 4 86-43-1
29
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
30
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
31
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
32
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
33
Rebamipide Investigational Phase 4 90098-04-7
34
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
35 Antacids Phase 4
36 Anti-Ulcer Agents Phase 4
37 Carboxymethylcellulose Sodium Phase 4
38 Plasma Substitutes Phase 4
39 Blood Substitutes Phase 4
40 Analgesics, Non-Narcotic Phase 4
41 Analgesics Phase 4
42 Anti-Inflammatory Agents, Non-Steroidal Phase 4
43 Dextrans Phase 4
44 Anticoagulants Phase 4
45 Carbopol 940 Phase 4
46 Laxatives Phase 4
47 Cathartics Phase 4
48 Guar Phase 4
49 Flax Phase 4
50 Cytochrome P-450 Enzyme Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 689)
# Name Status NCT ID Phase Drugs
1 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
2 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
3 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
4 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
5 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
6 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
7 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
8 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
9 A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis Unknown status NCT03237936 Phase 4 1mg/mL ciclosporin
10 Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
11 A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye Completed NCT02139033 Phase 4 Retaine™
12 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
13 Study to Evaluate the Physical Effect of SYSTANE QID in People That Have Moderate to Severe Dry Feeling Eyes Completed NCT00818909 Phase 4
14 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4
15 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
16 Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02986750 Phase 4
17 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
18 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
19 Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
20 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
21 The Comparison of 50 % Concentration Autologous Serum Eye Drops Versus Preservative Free Artificial Eye Drop Plus 0.05 % Cyclosporin Ophthalmic Emulsion in the Treatment of Severe Dry Eye Syndrome: A Randomized Comparative Study Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
22 Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca. Completed NCT01797822 Phase 4 Dexamethasone;Artificial tear
23 Soothe Versus Refresh Completed NCT00284999 Phase 4 Soothe;Refresh Tears
24 Refractive Surgery and Optive Compatibility Study Completed NCT00469157 Phase 4 Optive
25 A Randomized, Single-Center, Comparative Study of Rohto Dry-Aid® and Systane® Ultra in the Management of Tear Film Stability and Visual Function in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
26 Evaluation of Maintaining Visual Performance Of Subjects Who Engage in Electronic Visual Tasking While Using Restasis (EMPOWER) Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
27 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
28 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
29 Efficacy and Acceptability of Two Lubricant Eye Drops Completed NCT00756678 Phase 4 Lubricant Eye Drops (Optive™);Lubricating Eye Drops (blink® Tears)
30 Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
31 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
32 The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study Completed NCT00809198 Phase 4
33 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
34 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
35 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
36 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
37 Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Systane ® Ultra Preservative Free on Tear Film Dysfunction Syndrome From Mild to Moderate Completed NCT03223909 Phase 4 PRO-087;Systane Ultra;Systane Ultra Preservative Free
38 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
39 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
40 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
41 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
42 Efficacy, Tolerability and Comfort of 0.3% Hypromellose Eyedrops in the Pre- and Post-Operative Treatment of Patients Undergoing LASIK Surgery Completed NCT00909324 Phase 4 Pre-LASIK 0.3% hypromellose;Post-LASIK 0.3% hypromellose
43 Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye Completed NCT04091581 Phase 4 Systane Complete
44 Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients Completed NCT00520260 Phase 4 bromfenac;ketorolac
45 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
46 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
47 Evaluation of the Repeated Usage of Systane Ultra Eyedrop Completed NCT01051804 Phase 4
48 A Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye: A Randomized Controlled Trial Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
49 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
50 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis

Search NIH Clinical Center for Dry Eye Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cod Liver Oil
hydroxyethyl cellulose
retinol acetate
retinyl palmitate
Sodium Chloride
SODIUM CHLORIDE 0.9% PROCESSING SOLN
SODIUM CHLORIDE GRANULES
Vitamin A
VITAMIN A (AS ACETATE & BETA CAROTENE)
VITAMIN A (AS PALMITATE & BETA CAROTENE)
VITAMIN A (NATURAL)
VITAMIN A PALMITATE (SOLUBILIZED)

Cochrane evidence based reviews: dry eye syndromes

Genetic Tests for Dry Eye Syndrome

Anatomical Context for Dry Eye Syndrome

MalaCards organs/tissues related to Dry Eye Syndrome:

40
Eye, Testes, Salivary Gland, Thyroid, Bone, Bone Marrow, B Cells

Publications for Dry Eye Syndrome

Articles related to Dry Eye Syndrome:

(show top 50) (show all 1339)
# Title Authors PMID Year
1
Myopic regression and recurrent Salzmann nodule degeneration after laser in situ keratomileusis in Ehlers Danlos Syndrome. 61
32426553 2020
2
Arabinogalactan and hyaluronic acid in ophthalmic solution: Experimental effect on xanthine oxidoreductase complex as key player in ocular inflammation (in vitro study). 61
32380019 2020
3
Interactions of Perfluorohexyloctane With Polyethylene and Polypropylene Pharmaceutical Packaging Materials. 61
32240694 2020
4
Oculoplastic considerations for refractive procedures. 61
32487809 2020
5
Endocrine disrupting chemicals associated with dry eye syndrome. 61
31958513 2020
6
Quantification of changes in eyelid position in patients with dry eye syndrome: A randomized, placebo-controlled multicenter study of application of topical anesthetic. 61
32563539 2020
7
Hyaluronic Acid-Pluronic®F127-Laden Soft Contact Lenses for Corneal Epithelial Healing: In Vitro and In Vivo Studies. 61
32488761 2020
8
Commentary: Dry eye syndrome and vitamin D deficiency. 61
32461421 2020
9
Dose-response and normal tissue complication probabilities after proton therapy for choroidal melanomas. 61
32574763 2020
10
Dry Eye in Systemic Sclerosis Patients: Novel Methods to Monitor Disease Activity. 61
32545815 2020
11
Clinical manifestation and risk factors associated with remission in patients with filamentary keratitis. 61
32574776 2020
12
Methicillin-Resistant Staphylococcus aureus Keratitis: Initial Treatment, Risk Factors, Clinical Features, and Treatment Outcomes. 61
32209347 2020
13
Infrared thermography for the analysis of ocular surface temperature after phacoemulsification. 61
32049163 2020
14
Update of P2Y receptor pharmacology: IUPHAR Review 27. 61
32037507 2020
15
Fibromyalgia Syndrome and Eye - a review. 61
32512032 2020
16
In Vivo Effect of RSH-12, a Novel Selective MMP-9 Inhibitor Peptide, in the Treatment of Experimentally Induced Dry Eye Model. 61
32567381 2020
17
Umbilical Cord Blood and Serum for the Treatment of Ocular Diseases: A Comprehensive Review. 61
32107737 2020
18
Schirmer Paper Noninvasive Microsampling for Direct Mass Spectrometry Analysis of Human Tears. 61
32250596 2020
19
Interferometer eye image classification for dry eye categorization using phylogenetic diversity indexes for texture analysis. 61
31846832 2020
20
[Importance of Transient Receptor Potential Channels of the Ocular Surface: Insights and Outlook - from Laboratory Research to Clinical Practice]. 61
32289850 2020
21
A Novel Selective 11β-HSD1 Inhibitor, (E)-4-(2-(6-(2,6-Dichloro-4-(Trifluoromethyl)Phenyl)-4-Methyl-1,1-Dioxido-1,2,6-Thiadiazinan-2-yl)Acetamido)Adamantan-1-Carboxamide (KR-67607), Prevents BAC-Induced Dry Eye Syndrome. 61
32466320 2020
22
The use of tear ferning test in cats for evaluation of ocular surface. 61
32456655 2020
23
Ocular Findings in Pontine Tegmental Cap Dysplasia. 61
32398424 2020
24
Risk factors associated with severity of dry eye syndrome in ocular graft-versus-host disease. 61
32439193 2020
25
Sustained subconjunctival drug delivery systems: current trends and future perspectives. 61
32383131 2020
26
Ocular Complications in School-Age Children and Adolescents after Allogeneic Bone Marrow Transplantation. 61
32006482 2020
27
Intense pulsed light: results in chronic dry eye syndrome after LASIK. 61
32197872 2020
28
Vitamin D deficiency is associated with dry eye syndrome: a systematic review and meta-analysis. 61
32421222 2020
29
Efficacy of eye drops containing crosslinked hyaluronic acid and CoQ10 in restoring ocular health exposed to chlorinated water. 61
32064920 2020
30
A Mechanism Study of Electroacupuncture for Dry Eye Syndrome by Targeting Conjunctival Cytokine Expressions. 61
31557061 2020
31
The Effect of a Ptosis Procedure Compared to an Upper Blepharoplasty on Dry Eye Syndrome. 61
31770512 2020
32
[Assessment of the incidence of dry eye syndrome symptoms in Military Police soldiers serving outside the country]. 61
32352936 2020
33
Active matter therapeutics. 61
32346389 2020
34
The role of Interleukin 1 receptor antagonist in mesenchymal stem cell-based tissue repair and regeneration. 61
31755595 2020
35
Cryo-EM structure of the human PAC1 receptor coupled to an engineered heterotrimeric G protein. 61
32157248 2020
36
The association of dry eye syndrome and psychiatric disorders: a nationwide population-based cohort study. 61
32228638 2020
37
Risks of ophthalmic disorders in patients with systemic lupus erythematosus - a secondary cohort analysis of population-based claims data. 61
32160869 2020
38
Ocular involvement in systemic lupus erythematosus patients: a paradigm shift based on the experience of a tertiary referral center. 61
31992127 2020
39
Comparison of the efficacy of eyelid warming masks and artificial tears for dry eye symptoms in contact lens wearers. 61
32169321 2020
40
Economic impact of dry eye disease in Spain: A multicentre retrospective insurance claims database analysis. 61
32064919 2020
41
ICON: Diagnosis and management of allergic conjunctivitis. 61
31759180 2020
42
A new therapeutic approach for the Dry Eye Syndrome in patients with laryngopharyngeal reflux: first data. 61
32073559 2020
43
Association Between Dyslipidemia and Dry Eye Syndrome Among the Korean Middle-Aged Population. 61
31517720 2020
44
Effect of Diquafosol on Hyperosmotic Stress-induced Tumor Necrosis Factor-α and Interleukin-6 Expression in Human Corneal Epithelial Cells. 61
32037744 2020
45
Analysis of factors leading to lid wiper epitheliopathy. 61
32141525 2020
46
Serum growth factor stability in different eye drop packaging systems during storage. 61
31320279 2020
47
Ocular Surface Changes in Hashimoto's Thyroiditis Without Thyroid Ophthalmopathy. 61
32097187 2020
48
TEMPO-Oxidized Sacchachitin Nanofibers (TOSCNFs) Combined with Platelet-Rich Plasma (PRP) for Management of Dry Eye Syndrome. 61
32210562 2020
49
Changes in brainstem excitatory and inhibitory pathways in dry eye syndrome. 61
31884018 2020
50
Diagnosing the Dry Eye Syndrome in modern society and among patients with glaucoma: a prospective study. 61
32292856 2020

Variations for Dry Eye Syndrome

Expression for Dry Eye Syndrome

Search GEO for disease gene expression data for Dry Eye Syndrome.

Pathways for Dry Eye Syndrome

Pathways related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 TNF S100A9 S100A8 S100A11 ORM1 MUC1
2
Show member pathways
13.78 TNF PIP NGF MUC1 IL6 HGF
3
Show member pathways
13.49 TNF NGF IL6 HGF FGF7 FGF2
4
Show member pathways
13.35 TNF PIP NGF IL6 HGF FGF7
5
Show member pathways
13.31 TNF MUC1 IL6 HGF FGF7 FGF2
6
Show member pathways
13.27 NGF IL6 HGF FGF7 FGF2 EGF
7
Show member pathways
13.26 TNF PIP NGF IL6 HGF FGF7
8
Show member pathways
13.21 TNF NGF IL6 HGF FGF7 FGF2
9
Show member pathways
13.03 NGF IL6 HGF FGF7 FGF2 EGF
10
Show member pathways
13.01 NGF IL6 HGF FGF7 FGF2 EGF
11
Show member pathways
12.84 TNF NGF IL6 HGF FGF7 FGF2
12 12.78 IL6 HGF FGF7 FGF2 EGF
13
Show member pathways
12.69 NGF HGF FGF7 FGF2 EGF BDNF
14 12.67 TNF NGF HGF FGF7 FGF2 EGF
15
Show member pathways
12.38 TNF NGF IL6 HGF FGF7 FGF2
16
Show member pathways
12.32 NGF IL6 HGF FGF7 FGF2 EGF
17
Show member pathways
12.28 TNF S100A9 S100A8 IL6
18 12.25 TNF HGF FGF2 CD44
19 12.13 TNF NGF IL6 BDNF
20
Show member pathways
12.12 TNF NGF IL6 HGF FGF7 FGF2
21 12.02 IL6 HGF FGF7 FGF2 EGF
22 11.89 TNF MUC1 IL6 HGF FGF2
23 11.85 IL6 FGF2 EGF CD44
24
Show member pathways
11.74 TNF NGF BDNF
25 11.62 NGF FGF2 EGF CD44 BDNF
26 11.52 TNF IL6 FGF7
27 11.51 IL6 HGF FGF2 EGF
28 11.5 TNF IL6 HGF
29 11.49 NGF IL6 HGF FGF7 FGF2 EGF
30 11.43 FGF7 FGF2 EGF
31 11.39 HGF EGF AQP5
32 10.9 TNF IL6 HGF FGF7 FGF2 EGF
33 10.51 TNF PIP NGF IL6 HGF FGF7

GO Terms for Dry Eye Syndrome

Cellular components related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 TNF S100A9 S100A8 S100A11 PRR4 PIP
2 extracellular exosome GO:0070062 9.85 S100A9 S100A8 S100A11 PIP ORM1 MUC1
3 extracellular space GO:0005615 9.55 TNF S100A9 S100A8 S100A11 PRR4 PIP
4 platelet alpha granule lumen GO:0031093 9.43 ORM1 HGF EGF

Biological processes related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.04 TNF PIP NGF IL6 EGF
2 neutrophil degranulation GO:0043312 9.97 S100A9 S100A8 S100A11 ORM1 LTF CD44
3 cytokine-mediated signaling pathway GO:0019221 9.95 TNF MUC1 IL6 HGF FGF2
4 MAPK cascade GO:0000165 9.92 TNF HGF FGF7 FGF2 EGF
5 defense response to bacterium GO:0042742 9.91 TNF S100A9 S100A8 LTF LACRT
6 inflammatory response GO:0006954 9.91 TNF S100A9 S100A8 ORM1 IL6 CD44
7 activation of MAPK activity GO:0000187 9.84 TNF HGF FGF2 EGF
8 negative regulation of apoptotic process GO:0043066 9.8 NGF LTF LACRT IL6 HGF CD44
9 positive regulation of osteoblast differentiation GO:0045669 9.79 LTF IL6 HGF
10 positive regulation of MAP kinase activity GO:0043406 9.79 TNF FGF2 EGF
11 humoral immune response GO:0006959 9.78 TNF LTF IL6
12 antimicrobial humoral response GO:0019730 9.77 S100A9 S100A8 LTF
13 positive chemotaxis GO:0050918 9.77 HGF FGF7 FGF2
14 positive regulation of protein kinase B signaling GO:0051897 9.77 TNF HGF FGF7 FGF2 EGF
15 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.76 TNF S100A9 S100A8 NGF
16 negative regulation of interleukin-6 production GO:0032715 9.74 TNF ORM1 HGF
17 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.72 TNF S100A9 S100A8 LTF IL6
18 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.71 TNF NGF HGF CD44
19 positive regulation of neuroinflammatory response GO:0150078 9.65 TNF IL6
20 negative regulation of lipopolysaccharide-mediated signaling pathway GO:0031665 9.65 LTF LACRT
21 leukocyte migration involved in inflammatory response GO:0002523 9.65 S100A9 S100A8
22 regulation of protein localization to cell surface GO:2000008 9.64 EGF BDNF
23 negative regulation of lipid storage GO:0010888 9.63 TNF IL6
24 regulation of immune system process GO:0002682 9.63 PIP ORM1
25 positive regulation of collateral sprouting GO:0048672 9.62 NGF BDNF
26 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.58 HGF FGF7
27 sequestering of zinc ion GO:0032119 9.58 S100A9 S100A8
28 chemokine production GO:0032602 9.56 S100A9 S100A8
29 neutrophil aggregation GO:0070488 9.48 S100A9 S100A8
30 retina homeostasis GO:0001895 9.46 PRR4 PIP LTF LCN1
31 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.35 TNF NGF IL6 CD44 BDNF
32 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.1 LACRT IL6 HGF FGF7 EGF CD44

Molecular functions related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TNF S100A9 S100A8 S100A11 PIP ORM1
2 RAGE receptor binding GO:0050786 9.4 S100A9 S100A8
3 arachidonic acid binding GO:0050544 9.32 S100A9 S100A8
4 Toll-like receptor 4 binding GO:0035662 9.26 S100A9 S100A8
5 growth factor activity GO:0008083 9.23 NGF LACRT IL6 HGF FGF7 FGF2
6 nerve growth factor receptor binding GO:0005163 9.16 NGF BDNF
7 chemoattractant activity GO:0042056 9.13 HGF FGF7 FGF2

Sources for Dry Eye Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....